Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.04
$0.06
$0.01
▼
$0.09
$2.86M10.07104,302 shs7,202 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
+1.75%-36.41%-37.86%+307.00%+299.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.04
$0.06
$0.01
▼
$0.09
$2.86M10.07104,302 shs7,202 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
+1.75%-36.41%-37.86%+307.00%+299.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$12.45M0.23N/AN/A($0.91) per share-0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-$7.49M-$0.09N/AN/AN/A-38.78%N/A-31.18%N/A

Latest EMMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A$0.02N/A$0.02N/A$6.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A
0.09
0.07

Institutional Ownership

CompanyInstitutional Ownership
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
7.42%

Insider Ownership

CompanyInsider Ownership
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
35.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
3370.19 million45.62 millionNot Optionable

Recent News About These Companies

Emmaus, Cedars-Sinai Extend Pact
September 14, 2026  |  labusinessjournal.comL
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
August 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260831760299/en/Emmaus-Life-Sciences-Announces-Agreement-for-Evaluation-of-L-glutamine-for-Pancreatic-Cancer/
Emmaus Life Sciences Reports Quarterly Financial Results
May 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260515831708/en/emmaus-life-sciences-reports-quarterly-financial-results/
Emmaus Life Sciences Reports Annual Financial Results
March 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260330024056/en/emmaus-life-sciences-reports-annual-financial-results/
Emmaus Enters License and Exclusive Distribution Agreement with NeoImmuneTech
January 2, 2026  |  contractpharma.comC
Emmaus Life Sciences grants NeoImmuneTech Endari distribution rights
December 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/emmaus-life-sciences-grants-neoimmunetech-endari-distribution-rights/ar-AA1Tm4Ay
Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech
December 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/emmaus-life-sciences-enters-license-distribution-agreement-with-neoimmunetech/ar-AA1TjmxL
Emmaus, NIT sign Endari distribution agreement
December 31, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/emmaus-nit-sign-endari-distribution-095716124.html?fr=sycsrp_catchall
Emmaus Life Sciences restructures convertible debt via exchange
December 22, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/emmaus-life-sciences-restructures-convertible-debt-via-exchange?utm_source=marketbeat.com&utm_medium=referral
Emmaus Life Sciences Reports Quarterly Financial Results
November 14, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302616058.html
Emmaus Life Sciences Reports Quarterly Financial Results
August 14, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302530517.html
Emmaus Life Sciences Inc. Annual Income Statement - MarketWatch
July 9, 2025  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/emma/financials
Emmaus Life Sciences, Inc.: Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements - FinanzNachrichten.de
June 28, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65764356-emmaus-life-sciences-inc-emmaus-life-sciences-receives-fda-approval-for-endari-label-enhancements-008.htm
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
June 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-receives-fda-approval-for-endari-label-enhancements-302491840.html
Emmaus Life Sciences Reports Quarterly Financial Results
May 15, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
Emmaus Life Sciences Inc
April 18, 2025  |  uk.investing.comhttps://uk.investing.com/pro/OTCPK:EMMA/explorer/ebitda
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
January 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/emmaus-life-science-reports-grant-143000492.html
Emmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Improved Quarterly Financial Results
November 23, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63866824-emmaus-life-sciences-inc-emmaus-life-sciences-reports-improved-quarterly-financial-results-008.htm
Emmaus Life Sciences Reports Improved Quarterly Financial Results
November 19, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-improved-quarterly-financial-results-302310615.html
Mike Johnson impersonates Trump: ‘Make it too big to rig’
November 7, 2024  |  uk.news.yahoo.comhttps://uk.news.yahoo.com/mike-johnson-impersonates-trump-too-211448466.html

Media Sentiment Over Time

Emmaus Life Sciences stock logo

Emmaus Life Sciences OTCMKTS:EMMA

$0.04 0.00 (0.00%)
As of 10/28/2026 11:24 AM Eastern

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas